Disc Medicine Secures $30M Loan Drawdown, Extends Access to Additional Capital
IRON sits 83% above its 52-week low of $40.
Summary
Disc Medicine amended its loan agreement with Hercules Capital, drawing down $30 million immediately and extending the periods for accessing future loan tranches and amending cash covenants.
Key Events · Financing and Capital Events · IRON
-
Immediate $30 Million Loan Drawdown
The company agreed to immediately draw down $30,000,000 from its Tranche 1-B Advance under the amended loan agreement.
-
Extended Access to Future Capital
The existing $50,000,000 Tranche 1-C Advance was split into two $25,000,000 loans, available at the company's option through March 31, 2027, and April 30, 2027, respectively. Additionally, Tranche 2 and Tranche 3 advance periods were extended to December 15, 2027, and June 30, 2028.
-
Amended Minimum Cash Covenant
The minimum cash covenant terms were modified, pushing the initial testing date to July 1, 2028, providing greater operational flexibility.
Analysis · IRON · Life Sciences
Disc Medicine has secured an immediate $30 million loan drawdown and extended the availability of significant additional capital tranches into 2027 and 2028. This provides crucial financial flexibility and strengthens the company's cash runway, which is vital for a life sciences company with ongoing clinical development, especially following the recent FDA Complete Response Letter for bitopertin.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.6% of the 1216 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IRON was trading at $73.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $40.00 to $99.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.